focus -WSS

focus

author：explore 2025-09-30 16:59:37 - browse：5

Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research within the Food and Drug Administration, at a hearing — policy coverage from STAT — Peter Marks, director of the FDA's Center for Biologics Evaluation and Research Greg Nash/Pool via AP

WASHINGTON — A top Food and Drug Administration official wants Congress to dedicate full-time staff to emerging pathogens, after the FDA scrambled to find people for Covid-19 priorities like Operation Warp Speed.

“Vaccines were a pretty heavy duty lift during the pandemic,” said Peter Marks, director of the Center for Biologics Evaluation and Research, at a Thursday Politico event. “Rather than having to essentially reassign whole groups of people and disrupt things, the idea is to have a group of people who are constantly working on this.”

There is reason for optimism. Sens. John Hickenlooper (D-Colo.) and Ted Budd (R-N.C.) successfully added an amendment creating that team to a key pandemic preparedness bill that must be reauthorized by the end of September. It would establish this new program within Marks’ division of the FDA, staffed with experts on vaccines, antibodies, diagnostic tests, personal protective equipment, and other medical countermeasures. Among other activities, this team would enhance surveillance programs and prioritize vaccine research and development so that existing platforms can be retooled to fight other viruses.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： World's first CRISPR

leisure time

explore

WSS

FDA advisers back CAR

Readout Newsletter: CAR

Ebola: Gilead Sciences antiviral shows promise as new treatment

Why scientists need input from humanists on sensitive research

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Amid AI frenzy, a top HHS official's quest to create safeguards

explore

focus

hotspot

At least 13 dead in Texas as scorching temps continue

Morphosys mixed study results for blood cancer drug

Drug repurposing or repositioning? The language matters

Amid AI frenzy, a top HHS official's quest to create safeguards

Drug repurposing or repositioning? The language matters

U.K. considers world's first use of meningitis vaccine to address gonorrhea

Novavax promises a turnaround & Lilly roils the obesity market

Morphosys mixed study results for blood cancer drug

Guidelines to prevent youth baseball injuries need more muscle

In key trial, Verve's treatment lowers cholesterol levels in patients

hotspot

How to save health care price transparency rules

Readout Newsletter: CAR

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Steward Health Care Massachusetts hospitals face fiscal disaster

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

leisure time

explore

Wikipedia

knowledge